Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | CMKLR1 | Q99788 | 4/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177022 | 0.81 | HTR3A (0.48) | CMKLR1CYP4F2CYP4A11HTR3ATDP1 | |
| SCHEMBL25241376 | 0.78 | FGFR1 (0.37) | DGAT2CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL176777 | 0.78 | DGAT2 (0.37) | CMKLR1DGAT2CYP4F2CYP4A11HTR3A | |
| SCHEMBL25233771 | 0.77 | MEN1 (0.40) | DGAT2CYP4F2CYP4A11HTR3ARXRA | |
| SCHEMBL2237767 | 0.75 | HTR3A (0.46) | CYP4F2CYP4A11HTR3AELANE | |
| SCHEMBL2239274 | 0.72 | ELANE (0.45) | DGAT2ELANE | |
| SCHEMBL3339869 | 0.72 | CYP4F2 (0.41) | CYP4F2CYP4A11HTR3ARXRARXRB | |
| SCHEMBL257431 | 0.72 | ELANE (0.44) | ELANE | |
| SCHEMBL5207781 | 0.71 | MAPT (0.42) | DGAT2TDP1 | |
| SCHEMBL12090318 | 0.71 | ELANE (0.48) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | IGLV6-57 3200/4885ALKBH1 3659/4885SLC6A3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.